BUZZ - UBS raises AbbVie’s target price, citing expansion of its core business beyond the immunology drug sector
路透社2026/10/09 15:01On October 9, UBS raised its target price for AbbVie (ABBV.N) from $260 to $275, stating that investors' focus is shifting from blockbuster drugs Skyrizi and Rinvoq to the next wave of growth in its immunology business. UBS also noted that other projects in AbbVie’s R&D pipeline remain robust. It expects strong third-quarter performances from Skyrizi and Rinvoq, with respective sales reaching $5.7 billion and $2.7 billion. Special attention was given to upcoming combined treatment data of Skyrizi for Crohn's disease and ulcerative colitis, with mid-stage trial results to be released later this month. UBS believes that the drug lutikizumab, for inflammatory skin diseases, has a potential market size of $1-2 billion, and pointed out that Rinvoq sales are likely to surpass $500 million. The report also mentioned positive late-stage clinical data for cancer drugs Epkinly and etentamig, as well as the recent launch of the Parkinson’s disease medication tavapadon. UBS expects third-quarter earnings per share (EPS) to reach $3.76, within AbbVie’s forecast range of $3.73 to $3.77. Including intraday fluctuations, AbbVie’s stock has risen 21% so far this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. Due to potential inaccuracies or lack of required context in automated translations, Reuters does not guarantee the accuracy of these texts and is not liable for any damage or loss arising from their use. The translations are provided solely for readers' convenience.)
October 9 - ** UBS raises AbbVie (ABBV.N) price target from $260 to $275
** States that investor focus is shifting from blockbuster drugs Skyrizi and Rinvoq to the next wave of growth in the immunology business; notes that other projects in the R&D pipeline continue to show strong momentum
** Expects Skyrizi and Rinvoq to perform strongly in the third quarter, with sales projected to reach $5.7 billion and $2.7 billion, respectively
** Highlights upcoming data on Skyrizi's use in the combined treatment of Crohn's disease and ulcerative colitis, with mid-term trial results to be released later this month
** Believes that the drug lutikizumab for treating inflammatory skin diseases has a potential market size of $1 billion to $2 billion; points out that Rinvoq sales are likely to exceed $500 million
** Mentions positive late-stage clinical data for the cancer drugs Epkinly (link) and etentamig, as well as the recent launch of the Parkinson's disease treatment tavapadon (link)
** Expects third-quarter earnings per share (EPS) of $3.76, within AbbVie's forecast range of $3.73 to $3.77
** Including intraday fluctuations, the stock has risen 21% since the beginning of the year
(To facilitate non-English speakers, Reuters automates the translation of its reports into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the translated text, which is provided solely for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
United States Dollar Index remains subdued as lower oil prices ease inflation pressure
Silver Price Forecast: XAG/USD rises to near $53.00 as lower oil eases inflation pressure
Crypto prices
More
